JPS63316737A - Medicine composition for dermal administration - Google Patents
Medicine composition for dermal administrationInfo
- Publication number
- JPS63316737A JPS63316737A JP62151068A JP15106887A JPS63316737A JP S63316737 A JPS63316737 A JP S63316737A JP 62151068 A JP62151068 A JP 62151068A JP 15106887 A JP15106887 A JP 15106887A JP S63316737 A JPS63316737 A JP S63316737A
- Authority
- JP
- Japan
- Prior art keywords
- calcitonin
- calcitonins
- formulation
- absorbefacient
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 31
- 230000002500 effect on skin Effects 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title description 4
- 229940079593 drug Drugs 0.000 title description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000004094 surface-active agent Substances 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 239000003623 enhancer Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- -1 fatty acid esters Chemical class 0.000 abstract description 20
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract description 15
- 102000055006 Calcitonin Human genes 0.000 abstract description 14
- 108060001064 Calcitonin Proteins 0.000 abstract description 14
- 239000000839 emulsion Substances 0.000 abstract description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 10
- 229960004015 calcitonin Drugs 0.000 abstract description 10
- 239000011575 calcium Substances 0.000 abstract description 10
- 229910052791 calcium Inorganic materials 0.000 abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 6
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 5
- 239000000194 fatty acid Substances 0.000 abstract description 5
- 229930195729 fatty acid Natural products 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 208000037147 Hypercalcaemia Diseases 0.000 abstract description 3
- 230000000148 hypercalcaemia Effects 0.000 abstract description 3
- 208000030915 hypercalcemia disease Diseases 0.000 abstract description 3
- 239000002736 nonionic surfactant Substances 0.000 abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 3
- 208000029725 Metabolic bone disease Diseases 0.000 abstract description 2
- 229930003316 Vitamin D Natural products 0.000 abstract description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 2
- 210000004400 mucous membrane Anatomy 0.000 abstract description 2
- 235000019166 vitamin D Nutrition 0.000 abstract description 2
- 239000011710 vitamin D Substances 0.000 abstract description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 2
- 229940046008 vitamin d Drugs 0.000 abstract description 2
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 abstract 1
- 102000038379 digestive enzymes Human genes 0.000 abstract 1
- 108091007734 digestive enzymes Proteins 0.000 abstract 1
- 230000035987 intoxication Effects 0.000 abstract 1
- 231100000566 intoxication Toxicity 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 24
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 12
- DDPFHDCZUJFNAT-PZPWKVFESA-N chembl2104402 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CCCCCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 DDPFHDCZUJFNAT-PZPWKVFESA-N 0.000 description 11
- 108700032313 elcatonin Proteins 0.000 description 11
- 229960000756 elcatonin Drugs 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 6
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 5
- 108010068072 salmon calcitonin Proteins 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000047703 Nonion Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940045644 human calcitonin Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- KSIYPKPZIBBUFR-LJNLPFSOSA-N CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O Chemical compound CSCC[C@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(N)=O KSIYPKPZIBBUFR-LJNLPFSOSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000741447 Gallus gallus Calcitonin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940037448 calcitonin preparations Drugs 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- HMFKFHLTUCJZJO-UHFFFAOYSA-N 2-{2-[3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy}ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCC(OCCO)C1OCC(OCCO)C1OCCO HMFKFHLTUCJZJO-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- YBTVCUSZMGXJNW-FDNBCEJMSA-N C1=C2OCOC2=CC(/C=C\2/C(=C/C=3C=C4OCOC4=CC=3)/COC/2=O)=C1 Chemical compound C1=C2OCOC2=CC(/C=C\2/C(=C/C=3C=C4OCOC4=CC=3)/COC/2=O)=C1 YBTVCUSZMGXJNW-FDNBCEJMSA-N 0.000 description 1
- 102000017631 Calcitonin-like Human genes 0.000 description 1
- 108050005865 Calcitonin-like Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 101000910302 Sus scrofa Calcitonin Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MPVXINJRXRIDDB-VCDGYCQFSA-N dodecanoic acid;(2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCCCCCC(O)=O MPVXINJRXRIDDB-VCDGYCQFSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
[発明の目的]
(産業上の利用分野)
本発明は血清カルシウム低下作用を有するカルシトニン
類を有効成分とする経^投与用医薬組成物に関する。DETAILED DESCRIPTION OF THE INVENTION [Object of the Invention] (Industrial Field of Application) The present invention relates to a pharmaceutical composition for oral administration containing calcitonins having a serum calcium-lowering effect as an active ingredient.
(従来の技術)
カルシトニン類は血清カルシウム低下作用を有するペプ
チド類であって、高カルシウム血症、ビタミンD中毒、
代謝性骨疾患等に対する治療薬として使用されている。(Prior art) Calcitonins are peptides that have a serum calcium-lowering effect, and are associated with hypercalcemia, vitamin D toxicity,
It is used as a therapeutic agent for metabolic bone diseases, etc.
カルシトニン類には天然型カルシトニンまたはその類似
体が知られており、天然型カルシトニンの例としては、
ウナギカルシ1〜ニン、リケカルシトニン、ブタカルシ
トニン。Natural calcitonin or its analogs are known as calcitonins, and examples of natural calcitonin include:
Eel Calcitonin, Rike Calcitonin, Pig Calcitonin.
ヒトカルシトニン、ニワトリカルシトニン等が挙げられ
、また類似体としてはエルカトニン([aSu 1−7
]ウナギカルシトニン)、[asu 1−7 ]ヒト
カルシトニン等が知られている。Examples include human calcitonin, chicken calcitonin, and analogues include elcatonin ([aSu 1-7
] eel calcitonin), [asu 1-7 ] human calcitonin, and the like are known.
これらのカルシトニン類は消化管内あるいは消化管壁の
酵素により加水分解を受けるので、消化管からの吸収は
極めて困難である。したがって従来は注射剤投与に限ら
れていた。These calcitonins are hydrolyzed by enzymes in the gastrointestinal tract or on the wall of the gastrointestinal tract, so absorption from the gastrointestinal tract is extremely difficult. Therefore, conventional administration has been limited to injections.
しかしながら、注射剤投与は苦痛を伴なうので一般に好
まれず、また患者自身で投与することができないので、
連続投与の場合には不便であり、より簡便で適用しやす
い製剤が望まれた。However, injection administration is generally not preferred as it is painful and patients cannot administer it themselves.
Continuous administration is inconvenient, and a simpler and more easily applied formulation was desired.
そこで鼻、腔内に投与する形態の製剤が考えられ、吸収
促進剤として界面活性剤等を用いたインシュリンやカル
シトニン類の経鼻投与用液剤が報告されている。Therefore, preparations for nasal or intracavity administration have been considered, and liquid preparations for intranasal administration of insulin and calcitonins using surfactants and the like as absorption enhancers have been reported.
[1nt、 J、 Pharm、、 9.165−17
2(1981); Int、 J。[1nt, J. Pharm, 9.165-17
2 (1981); Int, J.
Pharm、、 9.173−184(1981);D
iabetes、 27.296−299(1978)
; J、 Japan Diab、 Soc、、 20
(2)、 14G −152(1977); N、
Enc+1. J、 Medl、 312.1078−
1084(1985): Diabetes、 20,
552−556(1971);Diabetes。Pharm, 9.173-184 (1981); D
iabetes, 27.296-299 (1978)
; J, Japan Diab, Soc, 20
(2), 14G-152 (1977); N,
Enc+1. J. Medl. 312.1078-
1084 (1985): Diabetes, 20,
552-556 (1971); Diabetes.
32、1040−1047(1983); Proc、
Natl、^cad、 Sci。32, 1040-1047 (1983); Proc.
Natl, ^cad, Sci.
U、S、へ1.工 NQ21.7419−7423.
(1985);持聞昭59−89619号公報;持聞昭
59−130820号公報、](発明が解決しようとす
る問題点)
しかしながら上記経鼻投与剤は、吸収促進剤として製剤
中に含有する非イオン性エーテル型界面活性剤や胆汁酸
のナトリウム塩が鼻粘膜に対し強い組織障害性を有する
ので、実際の適用は不可能であり、現在までに実用化に
至っているものは殆どない。U, S, to 1. Engineering NQ21.7419-7423.
(1985); Jimon Sho 59-89619; Jimon Sho 59-130820,] (Problems to be solved by the invention) However, the above-mentioned nasally administered preparation contains an absorption enhancer in the formulation. Since nonionic ether type surfactants and sodium salts of bile acids have strong tissue-damaging properties to the nasal mucosa, their actual application is impossible, and almost none have been put into practical use to date.
本発明は上記問題に対処してなされたもので、カルシト
ニン類を有効成分とする鼻腔内投与製剤において、鼻腔
粘膜に対し障害性がない製剤を提供することにより従来
技術における問題点を解決するものである。The present invention has been made in response to the above-mentioned problems, and aims to solve the problems in the prior art by providing an intranasal preparation containing calcitonins as an active ingredient that does not cause any damage to the nasal mucosa. It is.
[発明の構成]
゛ (問題点を解決するための手段あJ、び作用)本発
明者らは、カルシトニン類の経鼻投与に関し、の膣粘膜
に障害性のない製剤を種々検問した結果、1−ドデシル
アザシクロヘプタン−2−オンを吸収促進剤として添加
することにより、かかる目的に適った製剤が得られるこ
とを見出し、本発明に至った。[Structure of the Invention] ゛ (Means and Effects for Solving the Problems) The present inventors have investigated various formulations for nasal administration of calcitonins that are not harmful to the vaginal mucosa, and have found that: It was discovered that by adding 1-dodecyl azacycloheptan-2-one as an absorption enhancer, a formulation suitable for this purpose can be obtained, and the present invention was achieved.
すなわら、本発明はカルシトニン類を有効成分とする経
榔投与用医薬組成物にd3いて、吸収促進剤として1−
ドデシルアザシクロヘプタン−2−オンを含有すること
を特徴とするものである。In other words, the present invention provides a pharmaceutical composition for intravenous administration containing calcitonins as an active ingredient, and 1-1 as an absorption enhancer.
It is characterized by containing dodecyl azacycloheptan-2-one.
本発明の有効成分であるカルシトニン類とは、血清カル
シウム低下作用を有するペプチドであればよく、種々の
天然型カルシl−ニレJ:たはそのペプチド類似体をい
う。Calcitonin, which is an active ingredient of the present invention, may be any peptide that has a serum calcium lowering effect, and refers to various natural calcitonins or peptide analogues thereof.
天然型力、ルシトニンの例としては、ウナギカルシトニ
ン、ヒトカルシトニン、サケカルシトニン。Examples of natural forms of lucitonin include eel calcitonin, human calcitonin, and salmon calcitonin.
ブタカルシトニンまたはニワトリカルシトニン等が挙げ
られる。Examples include porcine calcitonin and chicken calcitonin.
またそのペプチド類似体の例としては、[aSUl−7
]ウナギカルシトニン(WHO−船名:エルカトニン)
、 [ASU 1−7 ]サケカルシトニン、[A
SU 1−7 ] ヒトカ)Lシトニンマたハ[ASU
1−7 ] ]二ワ]〜リカルシ]−ニンが挙げられ
る。Further, as an example of the peptide analogue, [aSUl-7
] Eel calcitonin (WHO-ship name: Elcatonin)
, [ASU 1-7] salmon calcitonin, [A
SU 1-7 ] Hitoka) L cytonin mataha [ASU
1-7]]]-ricalci]-nin.
これらの物質や合成法は、例えば英国特許第15169
47号明細書、日本化学会第50春明年会1985年講
演予稿集■第947頁等に記載されている。ざらに、上
記以外のカルシトニン様ペプチドで血清カルシウム低下
作用を有するペプチドであれば本発明に使用できるもの
であり、広く母疾患、内分泌代謝疾患、消化器疾患等に
関与し高カルシウム血症、骨粗髭症における疼痛、骨ペ
ーチェッ1〜病等の治療に用いられている。These substances and synthetic methods are described, for example, in British Patent No. 15169.
No. 47 Specification, Proceedings of the 1985 Lecture of the 50th Spring Meinen Meeting of the Chemical Society of Japan ■, page 947, etc. In general, calcitonin-like peptides other than those mentioned above that have a serum calcium-lowering effect can be used in the present invention, and are widely involved in maternal diseases, endocrine metabolic diseases, gastrointestinal diseases, etc., and are associated with hypercalcemia, bone It is used for the treatment of pain in baldness, osteopecet's disease, etc.
本発明の組成物中のカルシトニンの濃度としては、一般
に5MRC単位/d〜10.000M RC単位/dの
濃度で、好ましくは、50M RC単位/d〜2、OO
OMRC単位/dである。投与量は0.05〜0.2d
/回が好ましく、投与回数は1日1〜3回が適当である
。The concentration of calcitonin in the compositions of the invention is generally between 5 MRC units/d and 10.000 M RC units/d, preferably between 50 M RC units/d and 2,000 M RC units/d.
OMRC unit/d. Dose is 0.05-0.2d
The administration frequency is preferably 1 to 3 times a day.
また1−ドデシルアザシクロヘプタン−2−オンは各種
医薬の経皮吸収促進剤として開発された薬剤であって、
抗炎症剤、抗生物質、抗菌剤、制癌剤の経皮吸収に対す
るその効果の検討例が報告されている(特公昭60−3
7092号)。In addition, 1-dodecyl azacycloheptan-2-one is a drug developed as a transdermal absorption enhancer for various pharmaceuticals.
Examples of studies on the effects of anti-inflammatory agents, antibiotics, antibacterial agents, and anticancer agents on percutaneous absorption have been reported (Japanese Patent Publication No. 60-3
No. 7092).
本発明者らはこの0.1〜5%含有エマルジョン液10
0mをつIナギのの腔内に投与後、2 /l li間、
48時間毎に解剖しての膣粘膜を顕微鏡により組織学的
に観察した結果、従来カルシトニン製剤において吸収促
進剤として使用されていた界面活性剤に比較して鼻腔粘
膜に対する障害度が低く、安全性が高いことがわかった
。The present inventors have found that this 0.1-5% emulsion liquid 10
After administration into the cavity of the eel at 0 m, for 2 /l li,
As a result of histological observation using a microscope of the vaginal mucosa dissected every 48 hours, it was found that the degree of damage to the nasal mucosa was lower than that of the surfactant used as an absorption enhancer in conventional calcitonin preparations, and it is safe. was found to be high.
この1−ドデシルアザシクロヘプタン−2−オンは水に
不溶であるので、カルシトニン類の吸収促進効果を充分
に発揮させるためには界面活性剤を用いて乳化液とする
。Since this 1-dodecyl azacycloheptan-2-one is insoluble in water, a surfactant is used to form an emulsion in order to fully exhibit the effect of promoting the absorption of calcitonins.
このようにして得られた組成物は、昇腔内に投与すると
有効成分であるカルシトニン類かの粘膜より効率よく吸
収され、かつ刺激の副作用をともなわない。When the composition thus obtained is administered intracavitally, the active ingredient calcitonin is efficiently absorbed through the mucous membranes and does not cause any irritating side effects.
1−ドデシルアゾシクロへブタン−2−オンの使用’b
21i (L、一般ニ0.005〜10% (W/ V
) 72度、好ましくは0.1〜5%濃度である。Use of 1-dodecyl azocyclohebutan-2-one'b
21i (L, general Ni 0.005-10% (W/V
) 72 degrees, preferably 0.1-5% concentration.
また乳化液の調製は公知の方法で行なうことができるが
、乳化剤として界面活性剤、レシチン類等を用いること
かできる。Further, the emulsion can be prepared by a known method, and surfactants, lecithins, etc. can be used as the emulsifier.
界面活性剤としては、非イオン活性剤が好ましく、例え
ば次のようなものが使用できる。As the surfactant, nonionic surfactants are preferred, and for example, the following can be used.
ポリオキシエチレンソルビタン脂肪酸エステル類として
は、例えば花王アトラス社製[ト1^SQL 1130
(POEソルビタンモノラウレート:トIL816.3
) 、 EHASOL 3130 (POE ソル
ビタンモノステアレート: l−I L 8 14.9
> 、 IWEEN 20 (POE (20)ソルビ
タンモノラウレート:HLB 16.7>、丁WEE
N 40 (P OE (20)ソルビタンモノパルミ
テー ト : トILB 15.6)、 1讐
EEN 60 (P OE (20)ソルビタン
モノステアレート二トIL8 14.9> 、 TWE
EN 80 (P OE (20)ソルビタンモノオレ
イト:I−ILB 15.0) 、日光ケミカルズ社
製NIKKOL TL−1010、TP−10、TS−
10、TO−108,日本油脂社製 ノニオン0T−2
21、ノニオン5T−221、ノニオンP1−221
、ノニオンLT−221などが挙げられる。As polyoxyethylene sorbitan fatty acid esters, for example, Kao Atlas Co., Ltd. [To1^SQL 1130]
(POE sorbitan monolaurate: IL816.3
), EHASOL 3130 (POE sorbitan monostearate: l-IL 8 14.9
>, IWEEN 20 (POE (20) sorbitan monolaurate: HLB 16.7>, Ding WEE
N 40 (P OE (20) Sorbitan monostearate IL8 14.9), TWE
EN 80 (P OE (20) sorbitan monooleate: I-ILB 15.0), NIKKOL TL-1010, TP-10, TS- manufactured by Nikko Chemicals
10, TO-108, Nonion 0T-2 manufactured by NOF Corporation
21, Nonion 5T-221, Nonion P1-221
, Nonion LT-221, and the like.
ポリオキシエチレン硬化ヒマシ油としては、例えば日光
ケミカルズ社製旧にに叶11cO−40(POE(40
)硬化ヒマシ油: HLB12.5) 、 Nlにに叶
HCO−30(POE (50)硬化ヒマシ油ニド(L
B13.5) 、 NIKKOL Ic0−60 (
P OE (60)硬化ヒマシ油:HLB14.0)
、日本油脂社製 ユニオックスHC−40゜ユニオック
スIC−50,ユニオックスlIc−60などが挙げら
れる。As the polyoxyethylene hydrogenated castor oil, for example, Nii Kano 11cO-40 (POE (40
) Hydrogenated castor oil: HLB12.5), Nl Ni-Ko HCO-30 (POE (50) Hydrogenated castor oil nide (L
B13.5), NIKKOL Ic0-60 (
P OE (60) Hydrogenated castor oil: HLB14.0)
, Uniox HC-40°, Uniox IC-50, Uniox IC-60, manufactured by NOF Corporation.
ポリオキシエチレンソルビット脂肪酸エステル類として
は、例えば日光ケミカルズ社製 NIKKOLGo−4
30(POE(30)ツルピッl−テトラオレエート=
11L8 11.5>、NIにKOL GO−440(
POE(40)ソルビットテトラオレエート HLB
12.5)、 NIKK叶GO−460(POE(6
0)ソルビットテトラオレエート;HLB 14.0
> 、 NIKKOL GL−1(POE (6)ソル
ビットラウレート:)−ILB 15.5>。Examples of polyoxyethylene sorbitol fatty acid esters include NIKKOL Go-4 manufactured by Nikko Chemicals Co., Ltd.
30 (POE (30) Tsurupit l-tetraoleate =
11L8 11.5>, KOL GO-440 (
POE (40) Sorbittetraoleate HLB
12.5), NIKK Kano GO-460 (POE (6
0) Sorbittetraoleate; HLB 14.0
>, NIKKOL GL-1 (POE (6) Sorbitlaurate:)-ILB 15.5>.
花王アトラス社製 At1ox 1045^ (PO
Eンルビトールオレイトーラウレート:HLB13.2
) 、 At1ox 1196 (POEソルビトール
オレイト二トILB 11.4> 、 G−1045
(POEソルビトールラウレート: HL 811.5
) 、 G−1441(POEソルビトールラノリン誘
脣体: HL B 14.0) f;トが挙げられる
。Kao Atlas At1ox 1045^ (PO
Enlubitol oleitol laurate: HLB13.2
), At1ox 1196 (POE sorbitol oleate ILB 11.4>, G-1045
(POE Sorbitol Laurate: HL 811.5
), G-1441 (POE sorbitol lanolin derivative: HLB 14.0) f;
ポリオキシエチレングリセリン脂肪酸エステル類として
は、例えば旧にKOL THGS−15(P OE (
15)グリセリンモノステアレート:トILB 13
.5> 。As polyoxyethylene glycerin fatty acid esters, for example, KOL THGS-15 (POE (
15) Glycerin monostearate: ILB 13
.. 5>.
旧にKOL THGS−5(POE(5)グルセリルモ
ノステアレート:HLB9.5>などが挙げられる。Old examples include KOL THGS-5 (POE (5) glyceryl monostearate: HLB9.5).
ポリエチレングリコール脂肪酸エステル類としては、例
えば、日光ケミカル社製N■ににOL HYL−110
(POE (IOHノラウレート: HLB 12.5
> 。As polyethylene glycol fatty acid esters, for example, Nini OL HYL-110 manufactured by Nikko Chemical Co., Ltd.
(POE (IOH nolaurate: HLB 12.5
>.
NIKKOL HYS−10(POE (10)モノス
テアレート:FIL8 11.0>、旧にKOL HY
S−40(POE (40)モノステアレート:HLB
17.5)などが挙げられる。NIKKOL HYS-10 (POE (10) Monostearate: FIL8 11.0>, formerly KOL HY
S-40 (POE (40) Monostearate: HLB
17.5), etc.
ポリオキシエチレンアルキルフェニルエーテル類として
は、例えば日光ケミカル社製 Nlにに叶NP−10(
P OE (10)ノニルフェニルエーテル:トILB
16.5>、NIKKOLOP−10(POE(1
0)オクチルフェニルエーテル:HLB 11.5)
、花王ア1〜ラス社製EHULGEN 810 (P
OEオクチルフエニール工−テ/Lr:1−ILB
13.1) 、 EHULGEN 911 (POE
ノニルフェニルエーテル: 1−ILB 13.7)
。Examples of polyoxyethylene alkyl phenyl ethers include Nl Ni Ni Kano NP-10 (manufactured by Nikko Chemical Co., Ltd.).
P OE (10) Nonylphenyl ether: ILB
16.5>, NIKKOLOP-10 (POE (1
0) Octylphenyl ether: HLB 11.5)
, EHULGEN 810 (P
OE Octyl Phenyl Tech/Lr:1-ILB
13.1), EHULGEN 911 (POE
Nonylphenyl ether: 1-ILB 13.7)
.
EHULGEN 930 (POE / 二)ttl
x 二)I、tエーテル:t−I LB15.1)
、 Emulgen 950 (POEノニルフェニ
ルエーテル:1−ILB 18.2>などがあげられ
る。EHULGEN 930 (POE/2)ttl
x 2) I, t ether: t-I LB15.1)
, Emulgen 950 (POE nonylphenyl ether: 1-ILB 18.2) and the like.
これらの非イオン界面活性剤の)−I L B fiは
8〜18、好ましくは10〜17である。)-I L B fi of these nonionic surfactants is 8-18, preferably 10-17.
これらを単独又は適宜組み合わせて使用してもよい。こ
れらの界面活性剤の使用量としては、1−ドデシルアザ
シクロヘプタン−2−オン1重量部に対して0.05〜
5重R部が好ましい。These may be used alone or in appropriate combination. The amount of these surfactants used is 0.05 to 1 part by weight of 1-dodecyl azacycloheptan-2-one.
A 5-fold R part is preferred.
増粘着剤としてはメチルセルロース、ヒドロキシプロピ
ルセルロース、カルボキシビニルポリマー、プロピレン
グリコール、グリセリン、ポリエチレングリコール、ポ
リビニルアルコール、ポリヒニルビロリドン、ゼラチン
、ヒト口キシプロピルメヂルセルロース、ヒドロキシプ
ロピルスターチ、プルラン、カルボキシメヂルセルロー
ス等が挙げられる。Thickening agents include methylcellulose, hydroxypropylcellulose, carboxyvinyl polymer, propylene glycol, glycerin, polyethylene glycol, polyvinyl alcohol, polyhinylpyrrolidone, gelatin, human xypropylmethylcellulose, hydroxypropyl starch, pullulan, carboxymethane. Examples include dillcellulose.
さらに安定剤、緩衝液、防腐剤等を加えることもできる
。Furthermore, stabilizers, buffers, preservatives, etc. can also be added.
安定剤としてα−シクロデキストリン、β−シクロデキ
ストリン、γ−シクロデキストリン等が挙げられる。Examples of the stabilizer include α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin.
緩衝液としては例えば酢酸、クエン酸、酒石酸等の有機
酸、リン酸、炭酸などの無りa酸、アスパラギン酸、グ
ルタミン酸、グリシン、ヒスチジン。Buffers include, for example, organic acids such as acetic acid, citric acid, and tartaric acid; acetic acids such as phosphoric acid and carbonic acid; aspartic acid, glutamic acid, glycine, and histidine.
塩酸アルギニンなどのアミノ酸等が挙げられる。Examples include amino acids such as arginine hydrochloride.
防腐剤としては、パラオキシ安息香酸メチル。Methyl paraoxybenzoate is a preservative.
パラオキシ支息@酸プロピル、パラオキシ安息香酸エチ
ルなどのパラベン類、2−フェニルエタノール、エチル
アルコール、クロロブタノールなどのアルコール類、塩
化ベンザルコニウム、塩化ベンゼトニウム、塩化セチル
ピリジニウム等のカチオン界面活性剤を使用してもよい
。Parabens such as propyl paraoxybenzoate and ethyl paraoxybenzoate, alcohols such as 2-phenylethanol, ethyl alcohol, and chlorobutanol, and cationic surfactants such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride are used. You may.
以上のほか、必要であれば水酸化ナトリウム。In addition to the above, add sodium hydroxide if necessary.
トリスアミノメタン、トリエタノールアミン等のアルカ
リおよび塩酸、酢酸、クエン酸、酒石酸等の酸にてDI
+を調節することにより製造される。DI with alkalis such as trisaminomethane and triethanolamine and acids such as hydrochloric acid, acetic acid, citric acid, and tartaric acid.
Manufactured by adjusting +.
これらの添加剤は、1−ドデシルアザシクロヘプタン−
2−オンを乳化して添加する場合には、ぞの乳化時ある
いは乳化後に添加して使用してもよい。1−ドデシルア
ナシクロへブタン−2−オンの乳化液の製造は、例えば
室温又は必要でおれば加熱して、それ自体公知の乳化方
法、例えば超音波ホモジナイザー、高速攪拌ホモジナイ
ザー。These additives include 1-dodecyl azacycloheptane-
When 2-one is emulsified and added, it may be added at the time of emulsification or after emulsification. The emulsion of 1-dodecylanacyclohebutan-2-one can be prepared, for example, at room temperature or, if necessary, with heating, using emulsification methods known per se, such as an ultrasonic homogenizer, a high-speed stirring homogenizer.
圧力式ホモシナイナー、コロイドミル等を用いて乳化す
ることによって行なわれる。This is done by emulsifying using a pressure homogenizer, colloid mill, etc.
一方、カルシ1−ニレ類は水溶性であるため、上記乳化
液の調製中おるいは調製後に添加済fI′i′すればよ
い。On the other hand, since Calci 1-elm is water-soluble, it can be added fI'i' during or after the preparation of the emulsion.
以上のようにしてカルシ1〜ニン類の経鼻投与製剤を1
qることかできる。As described above, intranasal administration preparations of calci 1 to nins were prepared as follows.
I can do q things.
またカルシトニン類含有経宍投与製剤は滴の用又は噴霧
用として用いるほか、ゲル状にして鼻腔内へ投与できる
。In addition, calcitonin-containing preparations for oral administration can be used as drops or sprays, or can be made into a gel and administered intranasally.
(実施例)
以下に実施例、実験例を挙げて、本発明を更に詳しく説
明するが、本発明はこれに限定されるものではない。(Example) The present invention will be explained in more detail with reference to Examples and Experimental Examples below, but the present invention is not limited thereto.
実施例 1
製剤1の調製
ポリオキシエヂレンソルビタンモノラウレート(TLI
O,日光ケミカルズ社製;トILB価16.7)100
mgと1−ドデシルアザシクロヘプタン−2−オン(ネ
ルソンリサーチ社製> 2.0gにpl+6.0等張
リン酸緩衝液を徐々に加え、バイオミキサー(日本精機
社製)で5!!l即することにより、1−ドデシルアザ
シクロヘプタン−2−オンの乳化液が得られる。これに
さらに、1)H6,0等張リン酸vU街液を加えて10
0rdlにメスアップし、2 w/v%1−ドデシルア
ナシクロへブタン−2−オン乳化液を調製した。Example 1 Preparation of Formulation 1 Polyoxyethylene sorbitan monolaurate (TLI
O, manufactured by Nikko Chemicals; ILB value 16.7) 100
Gradually add PL+6.0 isotonic phosphate buffer to 2.0 g of 1-dodecyl azacycloheptan-2-one (manufactured by Nelson Research), and immediately mix 5!!L with a biomixer (manufactured by Nippon Seiki). By doing this, an emulsion of 1-dodecyl azacycloheptan-2-one is obtained.To this, 1) H6,0 isotonic phosphoric acid vU street solution is added, and 10
The volume was increased to 0rdl to prepare a 2 w/v% 1-dodecylanacyclohebutan-2-one emulsion.
一方、エルカドロン1ooo巾位を精秤し、上記の2%
1−ドデシルアザシクロヘプタン−2−オン乳化液1(
7を加え、攪拌して本発明の製剤を得た。On the other hand, accurately weigh 1 ooo width of Elkadron, and 2% of the above
1-dodecyl azacycloheptan-2-one emulsion 1 (
7 was added and stirred to obtain the formulation of the present invention.
別に以下の第1表記載の1−ドデシルアザシクロヘプタ
ン−2−オン濃度の異なるエルカトニン含有経0投与製
剤を同様の方法により製造した。Separately, oral preparations containing elcatonin having different concentrations of 1-dodecyl azacycloheptan-2-one as shown in Table 1 below were manufactured in the same manner.
また、100tJ/rn1のエルカトニンを含有し、1
−ドデシルアザシクロヘプタン−2−オンを含まないブ
ランク製剤を同様に調製して対照とした。It also contains 100tJ/rn1 of elcatonin, and 1
A blank formulation without -dodecyl azacycloheptan-2-one was similarly prepared and served as a control.
第 1 表 以上の各製剤を用いて、以下の実験を行なった。Table 1 The following experiments were conducted using each of the above formulations.
丈旅叢−ユ
吸収促進に及ぼす1−ドデシルアザシクロヘプタン−2
−オン添加量の影響
実験動物及び(外方法
16〜18時間絶食させた体重200〜250gのウィ
スター系(Wistar)雄性ラットを一部4匹として
実験に供した。実験投与20分前にベンドパルビタール
(sO1rtg/Ky)を腹腔的投与して麻酔したのち
、平井らの方法[Int、 J、 pharm、9.1
65〜172(1981)]に従ってまず頚部を切開し
、気管にポリエチレンチューブを挿入、次に食道を一部
切開して同径の先端を密栓したチューブを挿入し、切開
部を接着剤(アロンアルフン・−)にて閉じておく、製
剤1で作製したカルシトニン経内投与液剤をマイクロシ
リンジを用いて外の孔よりカルシトニン10u/ 0.
1ml/Kgを投与し、直ちに外の孔をアロンアルファ
ーにて閉じた。Effect of 1-dodecyl azacycloheptane-2 on promotion of absorption
-Effects of the amount of ion added Experimental animals and four male Wistar rats weighing 200-250 g that had been fasted for 16-18 hours were used in the experiment. After intraperitoneal administration of Vital (sO1rtg/Ky) for anesthesia, the method of Hirai et al. [Int, J, pharm, 9.1
65-172 (1981)], first make an incision in the neck, insert a polyethylene tube into the trachea, then make a partial incision in the esophagus, insert a tube with a sealed end of the same diameter, and seal the incision with adhesive (Aron Alfon). -), and the intravenous solution of calcitonin prepared in Formulation 1 was injected into the external hole using a microsyringe at 10 u/0.
1 ml/Kg was administered, and the outer hole was immediately closed with Aron Alpha.
血中カルシウム濃度の測
採血は投与前5分と投与俊1時間、2時間、3時間、4
時間および6時間毎に経時的に大腿静脈より0.25−
づつ採血し、15,000r、p、m、 5分遠心分離
俊ぞの血漿0.1dを用いて原子吸光度S1にて血漿中
のカルシウム濃度を測定した。Blood calcium concentration was measured and collected 5 minutes before administration and 1 hour, 2 hours, 3 hours, and 4 hours after administration.
0.25- from the femoral vein over time and every 6 hours.
Blood was collected from each patient and centrifuged at 15,000 r, p, m for 5 minutes. Using 0.1 d of fresh plasma, the calcium concentration in the plasma was measured using atomic absorption S1.
結果を以下の第2表に示す。The results are shown in Table 2 below.
第 2 表
第2表から明らかなように、1−ドデシルアザシクロヘ
プタン−2−オンの添加により血中のカルシウム濃度は
対照試験結果と比較して有意に低下していることがわか
る。Table 2 As is clear from Table 2, the addition of 1-dodecyl azacycloheptan-2-one significantly lowers the blood calcium concentration compared to the control test results.
実施例 2
覧遺2五遷1
(1)1−ドデシルアザシクロヘプタン−2−オン・・
・5Itg
(2)l−1co−60(818価14.0 >
・・・5rI1g(3)マクロゴール 1 、500
・・・10η(4)酢酸ナトリウム
・・・1.91η(5)氷酢酸
・・・0.36ffg(6)パラオキ
シ安息香酸メチル ・・・1.36■(7)バラ
オキシ安息香酸プロピル ・・・0.164(8)
エルカトニン ・・・100HRC単位蒸
留水で全量を1dとする。Example 2 References 2 and 5 (1) 1-dodecyl azacycloheptan-2-one...
・5Itg (2) l-1co-60 (818 valence 14.0 >
...5rI1g (3) Macrogol 1, 500
...10η(4) Sodium acetate
...1.91η(5) Glacial acetic acid
...0.36ffg (6) Methyl paraoxybenzoate ...1.36■ (7) Propyl paraoxybenzoate ...0.164 (8)
Elcatonin: Make the total amount 1 d with 100 HRC units of distilled water.
上記の処方により、成分(1)〜(7)を蒸留水ととも
にバイオミキサーにかけて乳化液を調製し、これにエル
カトニンを加え溶解して製剤2とした。According to the above formulation, components (1) to (7) were mixed with distilled water in a biomixer to prepare an emulsion, and elcatonin was added and dissolved therein to obtain Formulation 2.
+!!ぷ12は100u/meのエルカトニンを含有し
た。+! ! P12 contained 100 u/me of elcatonin.
*t−+co−6o:ポリオキシエチレン(重合度60
)硬化とマシ油
夫厘■−λ
製剤3の調製
(1)1−ドデシルアザシクロヘプタン−2−オン・・
・5!rtg
(2)精製卵黄レシチン ・・・5■(
3) ’j ’) t ’) ン−10trtg(4)
クエン酸ナトリウム ・・・4.63η(
5)無水クエン酸 ・・・0.37
■(6)塩化ベンザルコニウム ・・・0.
11Irg(7)エルカトニン ・・・1
00HRC単位蒸留水で仝聞を1rIIlとする。*t-+co-6o: polyoxyethylene (polymerization degree 60
) Curing and machining ■-λ Preparation of formulation 3 (1) 1-dodecyl azacycloheptan-2-one...
・5! rtg (2) Purified egg yolk lecithin...5■(
3) 'j') t') n-10trtg(4)
Sodium citrate...4.63η(
5) Anhydrous citric acid...0.37
■(6) Benzalkonium chloride...0.
11Irg(7) Elcatonin...1
Make the volume 1rII with 00 HRC unit distilled water.
上記処方により、成分(1)〜(6)および蒸留水をバ
イオミキサーにかけて乳化液を調製し、これにエルカト
ニンを加えて溶解し、pH6,0に調節して、製剤3と
した。製剤3は100u/dのエルカトニンを含有した
。According to the above formulation, components (1) to (6) and distilled water were mixed in a biomixer to prepare an emulsion, and elcatonin was added and dissolved therein, and the pH was adjusted to 6.0 to obtain Formulation 3. Formulation 3 contained 100 u/d of elcatonin.
(1)1−ドデシルアザシクロヘプタン−2−オン・・
・101r10
1rI Tween go −−
−1mg(3)にドロキシプロピルセルロース ・・
・10#Ig(4)グリシン
・・・2.0η(5)塩化ベンザルコニウム
・・・0.llft!j(6)サケカルシトニン
100HRC申位蒸留水で仝ωを1r111と
する。(1) 1-dodecyl azacycloheptan-2-one...
・101r10 1rI Tween go --
-1mg (3) of droxypropylcellulose...
・10#Ig(4) Glycine
...2.0η(5) Benzalkonium chloride
...0. llft! j(6) Salmon calcitonin
Set ω to 1r111 using 100 HRC level distilled water.
上記処方により、成分(1)〜(5)および蒸留水をバ
イオミキサーにかけて乳化し、こ・れにサケカルシトニ
ンを加え溶解してpl+ 5.0に調節し、100u
/ m(!のサケカルシトニンを含有する製剤4を1q
だ。According to the above formulation, components (1) to (5) and distilled water were emulsified using a biomixer, and salmon calcitonin was added and dissolved to adjust the pl+ to 5.0, and 100 u
/ m(!) of preparation 4 containing salmon calcitonin.
is.
*Twcen ao :ボリAキシエヂレン(20)ソ
ルビタンモノオレイト
(トILB 価 15.0 )
実験例 2
製剤2を市販の経書用メカニカルスプレーに充填した。*Twcen ao: polyA xyethylene (20) sorbitan monooleate (ILB value 15.0) Experimental Example 2 Formulation 2 was filled into a commercially available mechanical spray for bibliographies.
ニューシーラントホワイト系雄性ウサギ(体重2.5〜
3.0に9.1群4羽)のめ腔内に上記のように作成し
たカルシトニン経鼻投与組成物(製剤2)を100fi
ffi(1回の鼻腔内噴則聞)を投与した。New Sealant White male rabbit (weight 2.5~
100 fi of the calcitonin nasal administration composition (Formulation 2) prepared as above was placed in the eye cavity of 3.0 to 9.1 group (4 birds).
ffi (one intranasal injection) was administered.
また100LJ/dのエルカトニンを含有し、1−ドデ
シルアザシクロヘプタン−2−オンを含まないブランク
製剤を同様に調製しこれを製剤2と同様に投与した。In addition, a blank formulation containing 100 LJ/d of elcatonin and no 1-dodecyl azacycloheptan-2-one was similarly prepared and administered in the same manner as Formulation 2.
投与前および投与後1時間、2時間、3時間、4時間、
6時間毎につ1ナギ耳動脈より2,5dづつ採血した。1 hour, 2 hours, 3 hours, 4 hours before administration and after administration,
Blood was collected for 2.5 days from the ear artery every 6 hours.
採血後15,0OOr、 p、 m、、5分間遠心分離
して血漿を11だ。After blood collection, centrifuge at 15,0 OOr, p, m, for 5 minutes to collect plasma.
血漿中のカルシウム濃度の測定は原子吸光光度訓を用い
て行なった。Measurement of calcium concentration in plasma was performed using atomic absorption spectrophotometry.
なお、血中のカルシウム濃度の基準値(100%)は投
与5分曲に採血した値を示した。The reference value (100%) of the blood calcium concentration was the value obtained by collecting blood 5 minutes after administration.
b)結果
図面にブランク製剤の鼻粘膜投与(=ロー)と製剤2の
鼻粘膜投与(−0−)後の血中カルシウム濃度の変化率
を示した。b) Results The diagram shows the rate of change in blood calcium concentration after administering the blank formulation to the nasal mucosa (=low) and administering Formulation 2 to the nasal mucosa (-0-).
図面から明らかなように、本発明による吸収促進剤の添
加により血中のカルシウム濃度はブランク製剤の結果と
比較して有意に低下していることがわかる。As is clear from the drawings, it can be seen that the addition of the absorption enhancer according to the present invention significantly lowers the blood calcium concentration compared to the results of the blank preparation.
[発明の効果]
以上説明したように、本発明は吸収促進剤とLノで1−
ドデシルアザシクロヘプタン−2−オンを用いたことに
より、吸収性のよいかつ鼻腔粘膜に障害性のない経鼻投
与用カルシトニン製剤を1qることかでき、カルシトニ
ン類の経鼻投与剤の実用化が可能となった。[Effects of the Invention] As explained above, the present invention has an absorption enhancer and a 1-
By using dodecyl azacycloheptan-2-one, it is possible to produce 1 q of calcitonin preparations for nasal administration that are highly absorbable and do not cause any damage to the nasal mucosa. It has become possible.
図は本発明の製剤と1−ドデシルアザシクロヘプタン−
2−71ンを含有しない製剤くブランク)との各々をウ
サギに投与したときの血中カルシウム濃度の変化を示す
グラフである。
(8733)代理人 弁理士 猪 股 祥 晃(ばか
1名)
峙1’J’l (Hr)The figure shows the formulation of the present invention and 1-dodecyl azacycloheptane.
2 is a graph showing changes in blood calcium concentration when a formulation containing no 2-71 and a blank) were administered to rabbits. (8733) Agent Patent Attorney Yoshiaki Inomata (Baka
1 person) Face 1'J'l (Hr)
Claims (2)
組成物において、吸収促進剤として1−ドデシルアザシ
クロヘプタン−2−オンを含有することを特徴とする経
鼻投与用医薬組成物。(1) A pharmaceutical composition for nasal administration containing calcitonins as an active ingredient, which is characterized by containing 1-dodecyl azacycloheptan-2-one as an absorption enhancer.
面活性剤により乳化されている特許請求の範囲第1項記
載の経鼻投与用医薬組成物。(2) The pharmaceutical composition for nasal administration according to claim 1, wherein 1-dodecyl azacycloheptan-2-one is emulsified with a surfactant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62151068A JPS63316737A (en) | 1987-06-19 | 1987-06-19 | Medicine composition for dermal administration |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62151068A JPS63316737A (en) | 1987-06-19 | 1987-06-19 | Medicine composition for dermal administration |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS63316737A true JPS63316737A (en) | 1988-12-26 |
Family
ID=15510604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62151068A Pending JPS63316737A (en) | 1987-06-19 | 1987-06-19 | Medicine composition for dermal administration |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS63316737A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995033474A1 (en) * | 1994-06-03 | 1995-12-14 | Tsumura & Co. | Medicinal composition |
WO2004002444A3 (en) * | 2002-06-27 | 2004-03-11 | Holden Dev Ltd | A platform for transdermal formulations (ptf) |
WO2008038644A1 (en) | 2006-09-27 | 2008-04-03 | Asahi Kasei Pharma Corporation | Agent for preventing development of reflex sympathetic dystrophy after stroke |
WO2011062073A1 (en) | 2009-11-18 | 2011-05-26 | 旭化成ファーマ株式会社 | Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis |
-
1987
- 1987-06-19 JP JP62151068A patent/JPS63316737A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995033474A1 (en) * | 1994-06-03 | 1995-12-14 | Tsumura & Co. | Medicinal composition |
WO2004002444A3 (en) * | 2002-06-27 | 2004-03-11 | Holden Dev Ltd | A platform for transdermal formulations (ptf) |
WO2008038644A1 (en) | 2006-09-27 | 2008-04-03 | Asahi Kasei Pharma Corporation | Agent for preventing development of reflex sympathetic dystrophy after stroke |
WO2011062073A1 (en) | 2009-11-18 | 2011-05-26 | 旭化成ファーマ株式会社 | Preventative agent and/or therapeutic agent and/or exacerbation-suppressing agent for human knee osteoarthritis |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5158761A (en) | Spray gel base and spray gel preparation using thereof | |
US5215739A (en) | Spray gel base and spray gel preparation using thereof | |
KR100686901B1 (en) | Medicinal compositions for application to mucosa | |
DE69734653T2 (en) | PHARMACEUTICAL FORMULATION CONSISTING OF HUMAN GROWTH HORMONE, HISTIDINE AND NON-SPECIAL DETERGENT | |
JP5118633B2 (en) | Mucoadhesive xyloglucan-containing preparations useful in medical devices and pharmaceutical preparations | |
JPH01501550A (en) | Preparation for intranasal administration and method for producing the same | |
JPH06239748A (en) | Cetirizine-containing composition for antiallergic eye drop and nasal drop | |
CA2159209A1 (en) | Pharmaceutical composition containing lipophilic drugs | |
CA2315782A1 (en) | Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant | |
WO1995033474A1 (en) | Medicinal composition | |
CA2118655C (en) | Parathyroid hormone-containing emulsion for nasal administration | |
US9155697B2 (en) | Stable liquid compositions for treating stomatitis comprising epidermal growth factor | |
KR950000770B1 (en) | Calcitonin-containing emulsion for nasal administration | |
JPH07118166A (en) | Insulin composition | |
JP2006199589A (en) | Nanoparticle containing physiologically active protein or peptide, method for producing the same and external preparation comprising the nanoparticle | |
JPH04149126A (en) | Pharmaceutical composition for transmucous administration | |
AU608268B2 (en) | Nasal solutions | |
JPS63316737A (en) | Medicine composition for dermal administration | |
JPH01160916A (en) | Dopamine nasal administration preparation | |
JPS63303931A (en) | Drug preparation for transnasal administration having growth hormone releasing activity | |
JPH05170663A (en) | Medicine composition for calitonin rhinenchysis | |
JP3608802B2 (en) | Stable calcitonin pharmaceutical composition and method for producing the same | |
KR102513115B1 (en) | Composition for localized fat reduction comprising lithocholic acid | |
CN100371018C (en) | Calcitonin composition | |
JPH01230530A (en) | Liquid agent composition for nasal administration of calcitonin |